类固醇激素及拮抗剂调控子宫肌瘤神经标记物neurotrimin
实验室研究分析placebo和ulipristal acetate(UPA)治疗患者组织及体外细胞系,发现neurotrimin(NTM)在子宫肌瘤中较子宫肌层升高,雌激素和孕激素上调NTM蛋白,UPA治疗下调其表达,而fulvestrant无显著影响。
要点
- NTM在子宫肌瘤中表达高于匹配子宫肌层(RNASeq 5.22±0.57倍,qRT-PCR 1.95±0.05倍)。
- 17β-E2和孕激素分别上调肌瘤细胞NTM蛋白(1.98±0.11倍和1.91±0.97倍)。
- UPA治疗降低患者肌瘤NTM表达(RNASeq 0.75±0.14倍),fulvestrant无显著变化。
核心结论
- NTM在子宫肌瘤中较子宫肌层升高,雌激素和孕激素上调其表达,UPA治疗下调而fulvestrant无显著影响。
研究设计与样本
- 实验室研究,纳入placebo和UPA治疗患者组织及永生化子宫肌层和肌瘤细胞系。
主要发现
- RNASeq显示肌瘤NTM表达较肌层增加5.22±0.57倍,qRT-PCR确认1.95±0.05倍。
- 肌瘤组织NTM蛋白较匹配肌层升高2.799±0.575。
- 永生化肌瘤细胞系NTM蛋白上调2.4±0.04。
- 17β-E2处理肌瘤细胞系NTM蛋白增加1.98±0.11倍,fulvestrant无显著变化。
- 孕激素处理肌瘤细胞系NTM蛋白增加1.91±0.97倍,UPA处理患者肌瘤RNASeq表达降至0.75±0.14倍。
关键数值与推荐
- UPA治疗患者肌瘤组织IHC染色评分:UPA10 147.2±9.40,UPA20 182.8±8.98。
- UPA处理肌瘤细胞总NTM蛋白量为0.54±0.31,体外呈浓度依赖性效应。
临床怎么用
- 提示NTM可能作为孕激素和UPA调控的肌瘤相关标记物,但尚无临床决策阈值。
局限性
- 为实验室研究,样本量和患者特征未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the role of steroid hormone and antihormone exposure on neurotrimin (NTM) expression in human leiomyoma and myometrial tissue and cells. DESIGN: Laboratory study of placebo and ulipristal acetate (UPA)-treated patient tissue. In vitro assessment of immortalized myometrial and leiomyoma cell lines after hormone and antihormone exposure. SETTING: Academic research center. PATIENT(S): Not applicable. INTERVENTIONS(S): Exposure of leiomyoma cell lines to 17β-E2, medroxyprogesterone acetate (MPA), UPA, and fulvestrant. MAIN OUTCOME MEASURE(S): Messenger RNA expression quantified with the use of RNASeq analysis and quantitative real-time polymerase chain reaction (qRT-PCR). Protein levels quantified by means of Western blot analysis. Immunohistochemistry (IHC) on placebo- and UPA-treated patient uterine tissue specimens. RESULT(S): Expression of NTM in human uterine leiomyoma specimens according to RNASeq was increased compared with myometrium (5.22 ± 0.57-fold), which was confirmed with the use of qRT-PCR (1.95 ± 0.05). Furthermore, NTM protein was elevated in leiomyoma tissue compared with matched myometrium (2.799 ± 0.575). IHC revealed increased staining intensity in leiomyoma surgical specimens compared with matched myometrium of placebo patients. Western blot analysis in immortalized leiomyoma cell lines demonstrated an up-regulation of NTM protein expression (2.4 ± 0.04). Treatment of leiomyoma cell lines with 17β-E2 yielded a 1.98 ± 0.11-fold increase in NTM protein expression; however, treatment with fulvestrant showed no significant change compared with control. Leiomyoma cell lines demonstrated a 1.91 ± 0.97-fold increase in NTM protein expression after progesterone treatment. RNASeq analysis demonstrated a reduced expression in patient leiomyoma after UPA treatment (0.75 ± 0.14). Treatment of leiomyoma cells with UPA demonstrated a reduced total NTM protein amount (0.54 ± 0.31) in patients, which was confirmed with the use of IHC (UPA10 147.2 ± 9.40, UPA20 182.8 ± 8.98). In vitro studies with UPA treatment revealed a concentration-dependent effect that supported these findings. CONCLUSION(S): NTM, a neural cell adhesion molecule, is increased in leiomyoma compared with myometrium in patient tissue and in vitro models after estrogen and progesterone treatment. Down-regulation of expression occurs after UPA treatment, but not after fulvestrant exposure. CLINICAL TRIAL REGISTRATION NUMBER: NCT00290251.
引用
- Parikh TP, Malik M, Britten J, et al. Steroid hormones and hormone antagonists regulate the neural marker neurotrimin in uterine leiomyoma. Fertil Steril. 2020. PMID: 32033718. doi:10.1016/j.fertnstert.2019.08.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。